National Cancer Institute; Notice of Charter Renewal, 13305 [2019-06569]
Download as PDF
<![CDATA[
Federal Register / Vol. 84, No. 65 / Thursday, April 4, 2019 / Notices
Dated: March 29, 2019.
Lowell J. Schiller,
Acting Associate Commissioner for Policy.
grant of an Exclusive/Co-Exclusive
Patent License to practice the inventions
embodied in the Patents and Patent
Applications listed in the
Supplementary Information section of
this Notice to Senti Bio (‘‘Senti’’),
located in South San Francisco, CA.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before April 19, 2019 will be
considered.
[FR Doc. 2019–06549 Filed 4–3–19; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Charter Renewal
In accordance with Title 41 of the
U.S. Code of Federal Regulations,
Section 102–3.65(a), notice is hereby
given that the Charter for the Frederick
National Laboratory Advisory
Committee to the National Cancer
Institute was renewed for an additional
two-year period on March 30, 2019.
It is determined that the Frederick
National Laboratory Advisory
Committee to the National Cancer
Institute is in the public interest in
connection with the performance of
duties imposed on the National Cancer
Institute and National Institutes of
Health by law, and that these duties can
best be performed through the advice
and counsel of this group.
Inquiries may be directed to Claire
Harris, Acting Director, Office of Federal
Advisory Committee Policy, Office of
the Director, National Institutes of
Health, 6701 Democracy Boulevard,
Suite 1000, Bethesda, Maryland 20892
(Mail code 4875), Telephone (301) 496–
2123, or harriscl@nih.gov.
Dated: April 1, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–06569 Filed 4–3–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive/CoExclusive Patent License:
Development and Commercialization
of Next Generation Chimeric Antigen
Receptor (CAR) Therapies for the
Treatment of FMS-Like tyrosine kinase
3 (FLT3) Expressing Cancers
jbell on DSK30RV082PROD with NOTICES
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
SUMMARY:
VerDate Sep<11>2014
17:25 Apr 03, 2019
Jkt 247001
Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
Exclusive/Co-Exclusive Patent License
should be directed to: Jim Knabb, Senior
Technology Transfer Manager, NCI
Technology Transfer Center, 9609
Medical Center Drive, RM 1E530, MSC
9702, Bethesda, MD 20892–9702 (for
business mail), Rockville, MD 20850–
9702; Telephone: (240)–276–7856;
Facsimile: (240)–276–5504; Email:
jim.knabb@nih.gov.
SUPPLEMENTARY INFORMATION:
ADDRESSES:
Intellectual Property
E–133–2016: FLT3-Specific Chimeric
Antigen Receptors and Methods Using
Same
1. US Provisional Patent Application
62/342,394, filed May 27, 2016 (E–133–
2016–0–US–01);
2. International Patent Application
PCT/US2017/034,691, filed May 26,
2017 (E–133–2016–0–PCT–02)
3. EP Patent Application
No.:17729627.4, filed December 11,
2018 (E–133–2016/0–EP–03)
4. US Patent Application No.: 16/
304,552, filed November 26, 2018 (E–
133–2016/0–US–05
5. Australia Patent Application No.:
2017271606, filed November 13, 2018
(E–133–2016/0–AU–06)
6. Canadian Patent Application No.:
3025516, filed November 23, 2018 (E–
133–2016/0–CA–07)
7. Japan Patent Application No.:
2018–561669, filed November 22, 2018
(E–133–2016/0–JP–08)
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
The prospective exclusive/coexclusive license territory may be
worldwide, and the fields of use may be
limited to the following:
An exclusive license to: ‘‘the
development of a universal/split
chimeric antigen receptor (CAR)-based
immunotherapy using autologous or
allogeneic human lymphocytes (T cells
or NK cells) transduced with lentiviral
vectors, for the prophylaxis or treatment
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
13305
of cancers expressing FMS-like tyrosine
kinase 3 (FLT3; also known as CD135),
wherein the CAR construct binds to the
FLT3-binding domain referenced as
NC7 in the invention, but NC7 is not
included in the CAR construct.
Specifically excluded from the field of
use for this exclusive license are FLT3specific CAR -based immunotherapies
wherein the CAR construct comprises
the FLT3-binding domain referenced as
NC7 in the invention as well as an
intracellular signaling domain.’’ The
proposed territory is worldwide.
A co-exclusive license to: ‘‘the
development of a multi-specific FLT3
CAR-based immunotherapy using
autologous or allogeneic human
lymphocytes (T cells or NK cells)
transduced with lentiviral vectors,
wherein the viral transduction leads to
the expression of a CAR that targets
FLT3 (comprised of the FLT3-binding
domain referenced as NC7 in the
invention as well as an intracellular
signaling domain), for the prophylaxis
or treatment of FLT3-expressing
cancers.’’ The proposed territory is
worldwide.
A co-exclusive license to: ‘‘the
development of a FLT3-specific
Regulated/Switch/Logic-Gated CARbased immunotherapy using autologous
or allogeneic human lymphocytes (T
cells or NK cells) transduced with
lentiviral vectors, wherein the viral
transduction leads to the expression of
a CAR that targets FLT3 (comprised of
the FLT3-binding domain referenced as
NC7 in the invention as well as an
intracellular signaling domain), for the
prophylaxis or treatment of FLT3expressing cancers.’’ The proposed
territory is worldwide.
This technology discloses a CAR
therapy that targets FLT3 by utilizing
the anti-FLT3 binder known as NC7.
FLT3 (CD135) is a cytokine receptor
expressed on hematopoietic progenitor
cells and is one of the most frequently
mutated genes in acute myeloid
leukemia (AML) and infant acute
lymphoblastic leukemia (ALL). FLT3
mutation leads to increased cell surface
expression and therefore on leukemic
cells, which makes it an attractive
candidate for cellular therapies such as
CAR–T.
This Notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive/co-exclusive
license will be royalty bearing, and the
prospective exclusive/co-exclusive
license may be granted unless within
fifteen (15) days from the date of this
published Notice, the National Cancer
Institute receives written evidence and
argument that establishes that the grant
of the license would not be consistent
E:\FR\FM\04APN1.SGM
04APN1
]]>Agencies
[Federal Register Volume 84, Number 65 (Thursday, April 4, 2019)]
[Notices]
[Page 13305]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-06569]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Charter Renewal
In accordance with Title 41 of the U.S. Code of Federal
Regulations, Section 102-3.65(a), notice is hereby given that the
Charter for the Frederick National Laboratory Advisory Committee to the
National Cancer Institute was renewed for an additional two-year period
on March 30, 2019.
It is determined that the Frederick National Laboratory Advisory
Committee to the National Cancer Institute is in the public interest in
connection with the performance of duties imposed on the National
Cancer Institute and National Institutes of Health by law, and that
these duties can best be performed through the advice and counsel of
this group.
Inquiries may be directed to Claire Harris, Acting Director, Office
of Federal Advisory Committee Policy, Office of the Director, National
Institutes of Health, 6701 Democracy Boulevard, Suite 1000, Bethesda,
Maryland 20892 (Mail code 4875), Telephone (301) 496-2123, or
[email protected].
Dated: April 1, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-06569 Filed 4-3-19; 8:45 am]
BILLING CODE 4140-01-P
